These findings stand in contrast to prior data, showing no significant risk of thyroid cancer with semaglutide use, suggesting that differences in study design, population, and possibly the formulations of GLP-1 RAs used could contribute to these varying outcomes. Here, GLP1R is linked to thyroid cancer.